CA2704282A1 - Quinazolinone compounds and methods of use thereof - Google Patents

Quinazolinone compounds and methods of use thereof Download PDF

Info

Publication number
CA2704282A1
CA2704282A1 CA2704282A CA2704282A CA2704282A1 CA 2704282 A1 CA2704282 A1 CA 2704282A1 CA 2704282 A CA2704282 A CA 2704282A CA 2704282 A CA2704282 A CA 2704282A CA 2704282 A1 CA2704282 A1 CA 2704282A1
Authority
CA
Canada
Prior art keywords
chloro
compound
oxo
phenylamino
dihydroquinazolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2704282A
Other languages
English (en)
French (fr)
Inventor
Jifeng Liu
Syed M. Ali
Mark A. Ashwell
Ping Ye
Yousheng Guan
Shi-Chung Ng
Rocio Palma
Dan Yohannes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arqule Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2704282A1 publication Critical patent/CA2704282A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2704282A 2007-06-22 2008-06-19 Quinazolinone compounds and methods of use thereof Abandoned CA2704282A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US94583807P 2007-06-22 2007-06-22
US60/945,838 2007-06-22
PCT/US2008/067571 WO2009002808A2 (en) 2007-06-22 2008-06-19 Quinazolinone compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
CA2704282A1 true CA2704282A1 (en) 2008-12-31

Family

ID=39846620

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2704282A Abandoned CA2704282A1 (en) 2007-06-22 2008-06-19 Quinazolinone compounds and methods of use thereof

Country Status (13)

Country Link
US (1) US8232285B2 (enExample)
EP (1) EP2173724B1 (enExample)
JP (1) JP2010530885A (enExample)
KR (1) KR20100024494A (enExample)
CN (1) CN101801937A (enExample)
AU (1) AU2008268613A1 (enExample)
BR (1) BRPI0813355A2 (enExample)
CA (1) CA2704282A1 (enExample)
IL (1) IL202740A0 (enExample)
MX (1) MX2009013815A (enExample)
TW (1) TW200918069A (enExample)
WO (1) WO2009002808A2 (enExample)
ZA (1) ZA201000183B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5469779B2 (ja) * 2010-04-19 2014-04-16 エスアールアイ インターナショナル 多発性骨髄腫の治療のための組成物および方法
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20160685A1 (es) 2013-10-04 2016-07-23 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
US20150132575A1 (en) * 2013-11-14 2015-05-14 Honeywell International Inc. Luminescent fibers, articles including the same, and methods of forming the same
SG10201808053XA (en) 2014-03-19 2018-10-30 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US9708348B2 (en) 2014-10-03 2017-07-18 Infinity Pharmaceuticals, Inc. Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof
US10160761B2 (en) 2015-09-14 2018-12-25 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
EP3790878A1 (en) * 2018-05-11 2021-03-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Quinoline compounds and their preparation and use as antimalarial agents
CN113354590A (zh) * 2020-03-05 2021-09-07 宁波康柏睿格医药科技有限公司 拮抗nod1/2受体信号通路的喹唑啉酮类化合物

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BG16042A3 (bg) * 1968-11-12 1972-05-20 Nans Ott Метод за получаване на нови 2(1н)-хиназолинони
AU543928B2 (en) 1981-01-16 1985-05-09 Masayuki Ishikawa 4(311)-quinazolinone derivatives
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5187167A (en) * 1986-03-27 1993-02-16 Imperial Chemical Industries Plc Pharmaceutical compositions comprising quinazolin-4-one derivatives
GB8707053D0 (en) * 1987-03-25 1987-04-29 Ici Plc Anti-tumour agents
SK75289A3 (en) * 1988-02-10 1998-05-06 Hoffmann La Roche Substituted pyrroles, their use for producing a drug, and the drug on their base
GB8827820D0 (en) * 1988-11-29 1988-12-29 Janssen Pharmaceutica Nv (1h-azol-1-ylmethyl)substituted quinoline derivatives
GB8827988D0 (en) * 1988-11-30 1989-01-05 Smith Kline French Lab Chemical compounds
USRE36736E (en) * 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
GB8904161D0 (en) * 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
IL94274A0 (en) 1989-05-05 1991-03-10 Goedecke Ag Maleinimide derivatives,process for the preparation thereof and pharmaceutical compositions containing the same
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE4005969A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
IL98167A0 (en) * 1990-05-30 1992-06-21 Ici Plc Anti-tumour quinazoline derivatives,processes for their preparation and pharmaceutical compositions comprising them
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
US5591842A (en) * 1991-11-29 1997-01-07 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
ATE266033T1 (de) 1992-03-12 2004-05-15 Smithkline Beecham Plc N- (1-nbutyl-4-piperidyl)methyl -3,4-dihydro-2h- 1,3 oxazino 3,2-a indol-10-carboxamid oder ein pharmazeutisch annehmbares salz davon
AU3761393A (en) 1992-03-20 1993-10-21 Wellcome Foundation Limited, The Indole derivatives with antiviral activity
US5721230A (en) * 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
DK0817627T3 (da) 1993-12-23 2005-06-06 Lilly Co Eli Inhibitorer af proteinkinase C
US5545636A (en) * 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US6524832B1 (en) * 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
WO1995024190A2 (en) * 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
WO1995030682A1 (en) 1994-05-09 1995-11-16 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyprolocarbazole derivative
IL110831A (en) 1994-08-31 1998-12-27 Hadasit Med Res Service Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
US5591855A (en) * 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
IL112125A (en) 1994-12-22 1998-02-08 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions
US5559228A (en) * 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
KR20000064764A (ko) 1996-03-20 2000-11-06 피터지.스트링거 인돌릴말레이미드의제조방법
PE91598A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
PE91698A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
JP2000516632A (ja) 1996-08-23 2000-12-12 イーライ・リリー・アンド・カンパニー ビスインドリルマレイミド類の合成
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
WO1998016528A1 (en) 1996-10-11 1998-04-23 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US6028075A (en) 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
US5859261A (en) * 1997-03-20 1999-01-12 Eli Lilly And Company Synthesis of indolylmaleimides
US6184377B1 (en) * 1997-12-15 2001-02-06 Sepracor Inc. Compositions containing N-amino- and N-hydroxy-quinazolinones and methods for preparing libraries thereof
AU4929999A (en) 1998-07-30 2000-02-21 Japan Tobacco Inc. Disubstituted maleimide compounds and medicinal utilization thereof
AU2327700A (en) 1999-02-09 2000-08-29 Rei Asakai Pyrrole derivatives and cell death inhibitors
ES2263501T3 (es) 1999-10-27 2006-12-16 Cytokinetics, Inc. Procedimiento y composiciones que utilizan quinazolinonas.
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
DE60010934T2 (de) 1999-12-16 2005-05-19 Eli Lilly And Co., Indianapolis Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
US6867198B2 (en) * 1999-12-16 2005-03-15 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
EP1275646A4 (en) 2000-03-30 2003-05-28 Sagami Chem Res INDOLYLPYRROL DERIVATIVES AND CELL DEATH INHIBITORS
CA2408747C (en) 2000-05-11 2011-04-05 Consejo Superior Investigaciones Cientificas Heterocyclic inhibitors of glycogen synthase kinase gsk-3
AU7785401A (en) 2000-06-29 2002-01-14 Long Island Jewish Res Inst Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
US7074824B2 (en) 2001-07-31 2006-07-11 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
US6962944B2 (en) 2001-07-31 2005-11-08 Arqule, Inc. Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same
AU2002363429B2 (en) 2001-11-07 2008-05-08 Merck & Co., Inc. Mitotic kinesin inhibitors
WO2003043995A1 (en) 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
WO2003066808A2 (en) 2002-01-23 2003-08-14 Texas Tech University Mammalian migration inducting gene and methods for detection and inhibition of migrating tumor cells
AU2003213092A1 (en) 2002-02-15 2003-09-09 Smithkline Beecham Corporation Syntheses of quinazolinones
CA2477967C (en) 2002-03-05 2010-08-10 Eli Lilly And Company Purine derivatives as kinase inhibitors
JP2005530785A (ja) 2002-05-09 2005-10-13 サイトキネティクス・インコーポレーテッド 化合物、組成物、及び方法
EP1513820A4 (en) * 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
CA2485343A1 (en) * 2002-05-23 2004-05-13 Merck & Co., Inc. Mitotic kinesin inhibitors
US7211580B2 (en) 2002-07-23 2007-05-01 Cytokinetics, Incorporated Compounds, compositions, and methods
EP1620573A4 (en) 2003-04-15 2006-12-20 Avalon Pharmaceuticals DETERMINATION OF CANCER-ASSOCIATED GENES AND THERAPEUTIC OBJECTS USING MOLECULAR CYTOGENETIC PROCEDURES
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US7902192B2 (en) 2003-05-15 2011-03-08 Arqule, Inc. Inhibitors of P38 and methods of using the same
US7345046B2 (en) 2003-05-30 2008-03-18 Chiron Corporation Heteroaryl-fused pyrimidinyl compounds as anticancer agents
EP2093570A1 (en) 2003-06-06 2009-08-26 Genentech, Inc. Modulating the interaction between HGF beta chain and c-met
CA2539190A1 (en) 2003-07-07 2005-01-27 George F. Vande Woude Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
WO2005058965A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
EP2258704A1 (en) 2004-10-19 2010-12-08 ArQule, Inc. Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase
DK1846406T5 (da) 2005-02-09 2011-10-31 Arqule Inc Maleimidderivater, farmaceutiske sammensætninger og fremgangsmåder til behandling af cancer
ES2440953T3 (es) 2005-03-31 2014-01-31 The General Hospital Corporation Modulación de la actividad de HGF/HGFR para tratar un linfedema
WO2007123892A2 (en) * 2006-04-17 2007-11-01 Arqule Inc. Raf inhibitors and their uses

Also Published As

Publication number Publication date
BRPI0813355A2 (pt) 2014-12-30
JP2010530885A (ja) 2010-09-16
WO2009002808A2 (en) 2008-12-31
ZA201000183B (en) 2011-03-30
US8232285B2 (en) 2012-07-31
MX2009013815A (es) 2010-03-01
AU2008268613A1 (en) 2008-12-31
TW200918069A (en) 2009-05-01
EP2173724B1 (en) 2012-12-05
KR20100024494A (ko) 2010-03-05
WO2009002808A3 (en) 2009-07-23
US20090130097A1 (en) 2009-05-21
IL202740A0 (en) 2010-06-30
EP2173724A2 (en) 2010-04-14
CN101801937A (zh) 2010-08-11

Similar Documents

Publication Publication Date Title
EP2173724B1 (en) Quinazolinone compounds and methods of use thereof
US20110217300A1 (en) Quinazolinone Compounds and Methods of Use Thereof
CA2592286C (en) Quinazoline derivatives for inhibiting cancer cell growth and method for the preparation thereof
ES2376552T3 (es) Compuestos de quinazolinona como agentes antic�?ncer.
US7482343B2 (en) Compounds, methods and compositions
CA2388646C (en) Methods and compositions utilizing quinazolinones
Cai et al. Design and synthesis of novel 4-benzothiazole amino quinazolines Dasatinib derivatives as potential anti-tumor agents
CA2413426C (en) Methods and compositions utilizing quinazolinones
ES2369652T3 (es) Moduladores c-met y métodos de uso.
JP2005529076A (ja) キナゾリノンの合成
US20080021050A1 (en) Compounds, compositions, and methods
JP2005536475A (ja) 化合物、組成物、および方法
MX2007002433A (es) Derivados de quinazolinona y su uso como inhibidores de b-raf.
JP4792128B2 (ja) 癌に対するｈｓｐ９０阻害剤としての５−（２−ヒドロキシフェニル）テトラゾール
JP2011500603A5 (enExample)
US8916572B2 (en) Bis-quinazoline derivatives as inhibitors for epidermal growth factor receptor (EGFR) tyrosine kinase
Yassen et al. Molecular modelling and synthesis of quinazoline-based compounds as potential antiproliferative agents

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20130619